Market Overview:
The global medical foods for inborn errors of metabolism market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of inborn errors of metabolism, rising awareness about medical foods for inborn errors of metabolism, and technological advancements. The global medical foods for inborn errors of metabolism market is segmented by type, application, and region. By type, the market is segmented into amino acid-based products, glytactin with GMP-based products, amino acid-modified infant formula with iron-based products, low protein food products and others. The application segments include phenylketonuria (PKU), maple syrup urine disease (MSUD), urea cycle disorders (UCDs), renal diseases and others. Geographically, the global medical foods for inborn errors of metabolism market is segmented into North America,, Latin America,, Europe,, Asia Pacificand Middle East & Africa).
Product Definition:
A medical food is a food that is specifically designed to be used as a medical treatment for a particular disease or condition. Medical foods are often used to treat inborn errors of metabolism, which are rare genetic disorders that affect the way the body processes nutrients. Medical foods can help to prevent or treat the symptoms of these disorders by providing specialized nutrients that are not available in ordinary foods.
Amino Acid:
Amino acids are the basic building blocks for proteins. They are used in various foods and medical products. Some of the commonly used amino acids are histidine, lysine, and methionine among others.
Glytactin with GMP:
Glytactin with GMP is a prescription medicine used in the treatment of patients suffering from congenital metabolic disorders. These diseases are caused due to genetic mutations and improper functioning of essential enzymes involved in the catabolic pathway, which results in the accumulation of toxic levels of compounds (such as GBL, TBQ and 6-PG) into cells.
Application Insights:
Medical foods are used in the treatment of various disorders including phenylketonuria (PKU), maple syrup urine disease (MSUD), urea cycle disorders, and renal disease. Phenylalanine is a component of most human bodies and is an essential amino acid for humans. It is required for brain development, because it is an important precursor to several vital neurotransmitters such as dopamine & norepinephrine. PKU affects approximately 1 in 15,000 babies globally and 2-4 million people worldwide. There are two types of PKU; milder type which requires dietary management only while severer type needs both medical nutrition therapy along with dietary management through a specialized diet plan developed by a pediatrician or neurologist called Specialized Nutrition Dietitian (NND).
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing awareness levels regarding nutritional requirements are some of the major factors responsible for this dominance. Moreover, a rise in prevalence of metabolic disorders is also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, growing medical tourism industry due to low cost of treatment & high availability of skilled doctors is also expected boost demand for these products over next eight years.
Growth Factors:
- Increasing prevalence of inborn errors of metabolism (IEM)
- Growing awareness about medical foods for IEM
- Rising demand for personalized medicine
- Technological advancements in the field of medical foods for IEM
- Growing number of clinical studies on medical foods for IEM
Scope Of The Report
Report Attributes
Report Details
Report Title
Medical Foods for Inborn Errors of Metabolism Market Research Report
By Type
Amino Acid, Glytactin with GMP, Amino Acid-Modified Infant Formula With Iron, Low Protein Food, Others
By Application
Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Urea Cycle Disorders, Renal Disease, Others
By Companies
Nestlé, Abbott, Reckitt Benckiser Group, Ajinomoto, Solace Nutrition, Primus Pharmaceuticals, BioMarin Pharmaceutical, Danone SA, Galen Limited, PKU-MDMIL
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Medical Foods for Inborn Errors of Metabolism Market Report Segments:
The global Medical Foods for Inborn Errors of Metabolism market is segmented on the basis of:
Types
Amino Acid, Glytactin with GMP, Amino Acid-Modified Infant Formula With Iron, Low Protein Food, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Urea Cycle Disorders, Renal Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Nestlé
- Abbott
- Reckitt Benckiser Group
- Ajinomoto
- Solace Nutrition
- Primus Pharmaceuticals
- BioMarin Pharmaceutical
- Danone SA
- Galen Limited
- PKU-MDMIL
Highlights of The Medical Foods for Inborn Errors of Metabolism Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Amino Acid
- Glytactin with GMP
- Amino Acid-Modified Infant Formula With Iron
- Low Protein Food
- Others
- By Application:
- Phenylketonuria (PKU)
- Maple Syrup Urine Disease (MSUD)
- Urea Cycle Disorders
- Renal Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Medical Foods for Inborn Errors of Metabolism Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Medical foods are specially formulated and prepared to provide nutritional support for people with inborn errors of metabolism. These foods are specifically designed to help people with these conditions maintain a healthy weight, improve their energy levels, and manage their symptoms.
Some of the major companies in the medical foods for inborn errors of metabolism market are Nestl©, Abbott, Reckitt Benckiser Group, Ajinomoto, Solace Nutrition, Primus Pharmaceuticals, BioMarin Pharmaceutical, Danone SA, Galen Limited, PKU-MDMIL.
The medical foods for inborn errors of metabolism market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Medical Foods for Inborn Errors of Metabolism Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Medical Foods for Inborn Errors of Metabolism Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Medical Foods for Inborn Errors of Metabolism Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Medical Foods for Inborn Errors of Metabolism Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Medical Foods for Inborn Errors of Metabolism Market Size & Forecast, 2018-2028 4.5.1 Medical Foods for Inborn Errors of Metabolism Market Size and Y-o-Y Growth 4.5.2 Medical Foods for Inborn Errors of Metabolism Market Absolute $ Opportunity
Chapter 5 Global Medical Foods for Inborn Errors of Metabolism Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Type
5.2.1 Amino Acid
5.2.2 Glytactin with GMP
5.2.3 Amino Acid-Modified Infant Formula With Iron
5.2.4 Low Protein Food
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Medical Foods for Inborn Errors of Metabolism Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Applications
6.2.1 Phenylketonuria (PKU)
6.2.2 Maple Syrup Urine Disease (MSUD)
6.2.3 Urea Cycle Disorders
6.2.4 Renal Disease
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Medical Foods for Inborn Errors of Metabolism Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Medical Foods for Inborn Errors of Metabolism Analysis and Forecast
9.1 Introduction
9.2 North America Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Type
9.6.1 Amino Acid
9.6.2 Glytactin with GMP
9.6.3 Amino Acid-Modified Infant Formula With Iron
9.6.4 Low Protein Food
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Applications
9.10.1 Phenylketonuria (PKU)
9.10.2 Maple Syrup Urine Disease (MSUD)
9.10.3 Urea Cycle Disorders
9.10.4 Renal Disease
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Medical Foods for Inborn Errors of Metabolism Analysis and Forecast
10.1 Introduction
10.2 Europe Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Type
10.6.1 Amino Acid
10.6.2 Glytactin with GMP
10.6.3 Amino Acid-Modified Infant Formula With Iron
10.6.4 Low Protein Food
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Applications
10.10.1 Phenylketonuria (PKU)
10.10.2 Maple Syrup Urine Disease (MSUD)
10.10.3 Urea Cycle Disorders
10.10.4 Renal Disease
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Medical Foods for Inborn Errors of Metabolism Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Type
11.6.1 Amino Acid
11.6.2 Glytactin with GMP
11.6.3 Amino Acid-Modified Infant Formula With Iron
11.6.4 Low Protein Food
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Applications
11.10.1 Phenylketonuria (PKU)
11.10.2 Maple Syrup Urine Disease (MSUD)
11.10.3 Urea Cycle Disorders
11.10.4 Renal Disease
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Medical Foods for Inborn Errors of Metabolism Analysis and Forecast
12.1 Introduction
12.2 Latin America Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Type
12.6.1 Amino Acid
12.6.2 Glytactin with GMP
12.6.3 Amino Acid-Modified Infant Formula With Iron
12.6.4 Low Protein Food
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Applications
12.10.1 Phenylketonuria (PKU)
12.10.2 Maple Syrup Urine Disease (MSUD)
12.10.3 Urea Cycle Disorders
12.10.4 Renal Disease
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Medical Foods for Inborn Errors of Metabolism Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Type
13.6.1 Amino Acid
13.6.2 Glytactin with GMP
13.6.3 Amino Acid-Modified Infant Formula With Iron
13.6.4 Low Protein Food
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Medical Foods for Inborn Errors of Metabolism Market Size Forecast by Applications
13.10.1 Phenylketonuria (PKU)
13.10.2 Maple Syrup Urine Disease (MSUD)
13.10.3 Urea Cycle Disorders
13.10.4 Renal Disease
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Medical Foods for Inborn Errors of Metabolism Market: Competitive Dashboard
14.2 Global Medical Foods for Inborn Errors of Metabolism Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Nestlé
14.3.2 Abbott
14.3.3 Reckitt Benckiser Group
14.3.4 Ajinomoto
14.3.5 Solace Nutrition
14.3.6 Primus Pharmaceuticals
14.3.7 BioMarin Pharmaceutical
14.3.8 Danone SA
14.3.9 Galen Limited
14.3.10 PKU-MDMIL